Laurus Labs Q3 FY26: Revenue ₹1,778 Cr, Profit ₹252 Cr; 9M Revenue ₹5,001 Cr
Laurus Labs reported Q3 FY26 revenue of ₹1,778 Cr (up 26% YoY) and net profit of ₹252 Cr (up 174% YoY). For 9M FY26, revenue reached ₹5,001 Cr (up 30% YoY) and net profit was ₹610 Cr (up 388% YoY). EBITDA margins improved significantly for both periods. The company is investing in manufacturing expansion and advanced modalities.
The strong financial performance, including substantial growth in revenue and net profit, coupled with margin expansion and continued investment in future growth areas, is likely to have a significant positive impact on investor sentiment and the company's stock.
The company reported significant year-on-year growth in revenues, profits, and EBITDA margins for both the quarter and nine months ended December 31, 2025. Investments in expansion and advanced modalities are progressing well, indicating a positive outlook.
Laurus Labs Limited announced its financial results for the quarter and nine months ended December 31, 2025. For the third quarter of FY26, the company reported revenues of ₹1,778 crore, marking a 26% increase year-on-year, driven primarily by robust growth in the Generics division (both FDF & API business), supported by sustained performance in the CDMO segment. EBITDA for Q3 FY26 stood at ₹485 crore, a 70% increase year-on-year, with EBITDA margins improving by 720 basis points to 27.3%. Net profits surged by 174% to ₹252 crore. Gross margins expanded by 400 basis points to 60.9% due to a favorable divisional mix.
For the nine months ended December 31, 2025 (9M FY26), Laurus Labs achieved revenues of ₹5,001 crore, a 30% increase year-on-year. The company reported a 104% increase in EBITDA to ₹1,303 crore, with EBITDA margins at 26.1%, an improvement of 950 basis points. Net profits saw a significant jump of 388% to ₹610 crore. Gross margins for the nine-month period were 60.1%, an increase of 430 basis points. The company continued its investment in the manufacturing network and niche capabilities, with CAPEX at 15% of sales for 9M FY26, amounting to ₹735 crore.
The CDMO division's small molecules segment showed sustained demand, with a 2% year-on-year revenue growth for 9M FY26, while the Bio segment saw a 10% year-on-year decline. The Generics division demonstrated solid execution, with API revenue growing 13% and FDF revenue growing 48% in 9M FY26. The company also provided updates on its advanced modalities, including cell and gene therapy capabilities, with the second GMP facility in Navi Mumbai expected to commission by March 2026. Laurus Labs maintained its outlook for FY2026, expecting healthy operational growth driven by strong CDMO industry outlook, clinical and commercial business momentum, and Generics growth.
What to do with a filing like this
Laurus Labs Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Laurus Labs Limited. Read the original for the full detail.